Ocera Therapeutics Inc. founded in January 2005, is a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal and liver diseases.
Ocera’s goal is to develop safe and novel therapies that address significant unmet medical needs in the treatment of gastrointestinal and liver diseases. Ocera has assembled an executive management team with broad experience in developing and launching pharmaceutical products at both large and emerging growth companies. The company is organized to provide high efficiency in clinical development, regulatory affairs and licensing, with the goal of building a strong product pipeline, and developing compounds for accelerated commercialization of much-needed products for debilitating diseases.
|02/01/08||Series C||35.5M||Montagu Newhall Associates, InterWest Partners, AgeChem Venture Fund, Cross Creek Capital||Unknown|